According to a recent report by KDMI, Japan Oncology Drugs Market is anticipated to Boom by 2026

KD Market Insights has published a new report on  Japan Oncology Drugs Market analysis and forecast 2019-2026. The report comprises of Japan Oncology Drugs Market size, Y-o-Y growth analysis, and market dynamics, including growth drivers, restraining factors, opportunities, and trends which are spearheading current nature and future status of the market.

The Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.

Request for Sample @ https://www.kdmarketinsights.com/sample/5486

Cancer is a serious medical condition marked by the presence of tumor cells present in the body. The formation of tumor cells take place when the normal cells grow at an abnormal rate. Moreover, these tumor cells also have the ability to spread to other parts of the body through blood and lymphatic system. In addition, cancer has different stages which are based on the growth pattern of tumor. Therefore, the treatment of cancer differs depending on the stage of cancer. Chemotherapy drugs are mostly employed in the treatment of early stage cancers and similarly targeted therapy and immunotherapy drugs are generally preferred in the treatment of late stage cancers.

Surge in research related to new drug discovery for cancer treatment, rise in incidence of cancer in Japan, and increase in healthcare expenditure boost the growth of Japan oncology drugs market. Moreover, rise in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. Conversely, stringent approval process of oncology drugs in Japan hinders the growth of market.

The Japan oncology drugs market size is studied based on segments, drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.

KEY BENEFITS FOR STAKEHOLDERS

- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Japan market
- A qualitative analysis based on innovative products facilitates strategic business planning.

Key Market Segments

By Drug Class Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy

By Indication
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Lung Cancer
- Skin Cancer
- Ovarian Cancer
- Cervical Cancer
- Other Cancers

List of key players profiled in the report:

- Otsuka Holdings Co Ltd
- Johnson and Johnson
- Daiichi Sankyo Co Ltd
- AstraZeneca plc
- AbbVie Inc.
- Celgene Corporation
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Ltd

LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

- Sanofi
- Amgen Inc.
- Bayer AG

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/japan-oncology-drugs-market-amr

Table of Content

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Rise In Incidence of Cancer
3.4.1.2. Surge In Geriatric Population

3.4.2. Restraint

3.4.2.1. Stringent Approval Process

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast,

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast,

4.4. Immunotherapy

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast,

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast,

Chapter 5: Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.2.2. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities
5.3.2. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.4.1.1. Market Size And Forecast

5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.5.1.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.6.1.1. Market Size And Forecast

5.6.2. Small Cell Lung Cancer

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.7.1.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.8.1.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.9.1.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.10.1.1. Market Size And Forecast

5.11. Other Cancers

5.11.1. Key Market Trends, Epidemiology, Growth Factors And Opportunities

5.11.1.1. Market Size And Forecast

 Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/5486

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

Contact Us

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@kdmarketinsights.com

Website: www.kdmarketinsights.com

Read More News: http://kdmarketinsights.blogspot.com/

https://marketreserachtab.blogspot.com/